Phase I/II trial of QR-421a in patients with Usher syndrome type 2A.
Phase of Trial: Phase I/II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs QR-421a (Primary)
- Indications Usher syndromes
- Focus Adverse reactions; Therapeutic Use
- 28 Feb 2018 According to the ProQR Therapeutics media release, this trial is expected to start at the end of 2018.
- 14 Feb 2018 New trial record
- 12 Feb 2018 According to the ProQR Therapeutics, this trial expected to start in 2018 and results are expected in 2019.